Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RAP2C_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RAP2C_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RAP2C_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RAP2C_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
GO:000206420 | Esophagus | ESCC | epithelial cell development | 136/8552 | 220/18723 | 9.50e-07 | 1.21e-05 | 136 |
GO:004677710 | Esophagus | ESCC | protein autophosphorylation | 138/8552 | 227/18723 | 2.98e-06 | 3.38e-05 | 138 |
GO:000188510 | Esophagus | ESCC | endothelial cell development | 44/8552 | 64/18723 | 1.59e-04 | 1.05e-03 | 44 |
GO:006102818 | Esophagus | ESCC | establishment of endothelial barrier | 32/8552 | 46/18723 | 9.01e-04 | 4.61e-03 | 32 |
GO:00182124 | Esophagus | ESCC | peptidyl-tyrosine modification | 202/8552 | 378/18723 | 1.34e-03 | 6.39e-03 | 202 |
GO:00181084 | Esophagus | ESCC | peptidyl-tyrosine phosphorylation | 200/8552 | 375/18723 | 1.60e-03 | 7.45e-03 | 200 |
GO:00507303 | Esophagus | ESCC | regulation of peptidyl-tyrosine phosphorylation | 144/8552 | 264/18723 | 2.22e-03 | 9.78e-03 | 144 |
GO:00610972 | Esophagus | ESCC | regulation of protein tyrosine kinase activity | 55/8552 | 90/18723 | 2.27e-03 | 9.99e-03 | 55 |
GO:00319521 | Esophagus | ESCC | regulation of protein autophosphorylation | 29/8552 | 43/18723 | 3.25e-03 | 1.35e-02 | 29 |
GO:00319541 | Esophagus | ESCC | positive regulation of protein autophosphorylation | 19/8552 | 27/18723 | 8.35e-03 | 2.95e-02 | 19 |
GO:00905578 | Esophagus | ESCC | establishment of endothelial intestinal barrier | 10/8552 | 12/18723 | 8.94e-03 | 3.12e-02 | 10 |
GO:004544610 | Esophagus | ESCC | endothelial cell differentiation | 67/8552 | 118/18723 | 9.86e-03 | 3.40e-02 | 67 |
GO:000315818 | Esophagus | ESCC | endothelium development | 76/8552 | 136/18723 | 1.05e-02 | 3.59e-02 | 76 |
GO:000726521 | Liver | HCC | Ras protein signal transduction | 187/7958 | 337/18723 | 8.89e-07 | 1.35e-05 | 187 |
GO:00467775 | Liver | HCC | protein autophosphorylation | 123/7958 | 227/18723 | 2.40e-04 | 1.80e-03 | 123 |
GO:000206422 | Liver | HCC | epithelial cell development | 114/7958 | 220/18723 | 3.19e-03 | 1.47e-02 | 114 |
GO:006102822 | Liver | HCC | establishment of endothelial barrier | 28/7958 | 46/18723 | 9.16e-03 | 3.52e-02 | 28 |
GO:000188512 | Liver | HCC | endothelial cell development | 37/7958 | 64/18723 | 9.63e-03 | 3.63e-02 | 37 |
GO:00072659 | Oral cavity | OSCC | Ras protein signal transduction | 185/7305 | 337/18723 | 1.95e-09 | 4.60e-08 | 185 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAP2C | SNV | Missense_Mutation | | c.361G>C | p.Glu121Gln | p.E121Q | Q9Y3L5 | protein_coding | tolerated(0.08) | benign(0.072) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
RAP2C | SNV | Missense_Mutation | | c.427A>G | p.Met143Val | p.M143V | Q9Y3L5 | protein_coding | tolerated(0.25) | benign(0.003) | TCGA-EW-A1P0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD |
RAP2C | SNV | Missense_Mutation | | c.205G>A | p.Asp69Asn | p.D69N | Q9Y3L5 | protein_coding | deleterious(0) | benign(0.18) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
RAP2C | SNV | Missense_Mutation | | c.375G>T | p.Glu125Asp | p.E125D | Q9Y3L5 | protein_coding | tolerated(0.35) | possibly_damaging(0.662) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAP2C | SNV | Missense_Mutation | | c.437N>T | p.Ser146Leu | p.S146L | Q9Y3L5 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAP2C | SNV | Missense_Mutation | novel | c.9N>C | p.Glu3Asp | p.E3D | Q9Y3L5 | protein_coding | tolerated(0.16) | probably_damaging(0.933) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
RAP2C | SNV | Missense_Mutation | novel | c.403G>A | p.Ala135Thr | p.A135T | Q9Y3L5 | protein_coding | deleterious(0) | probably_damaging(0.92) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAP2C | SNV | Missense_Mutation | novel | c.133N>A | p.Glu45Lys | p.E45K | Q9Y3L5 | protein_coding | tolerated(0.08) | possibly_damaging(0.865) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAP2C | SNV | Missense_Mutation | | c.37G>A | p.Gly13Arg | p.G13R | Q9Y3L5 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-D1-A0ZS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAP2C | SNV | Missense_Mutation | rs781764495 | c.544N>A | p.Val182Ile | p.V182I | Q9Y3L5 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-D1-A167-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |